FibroBiologics, Inc. FBLG 深 滬
等待開盤 03-26 09:30:00 美东时间
0.2635
+0.006
+2.41%
華盛通- 最 高0.2699
- 今 開0.255
- 成交量 127.13万股
- 最 低 0.24
- 昨 收 0.2573
- 總市值 1781.12万
- 52周最高 1.53
- 市盈率 靜 --
- 換手率 1.88%
- 52周最低 0.2201
- 委 比 71.61%
- 總股本 6759.47万
- 歷史最高 55.00
- 量 比 1.56
- 振 幅 11.62%
- 歷史最低 0.2201
- 每 手 1
- 風險率 0.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FibroBiologics shares are trading lower after the company announced it approved a 1-for-20 reverse stock split.
FibroBiologics shares are trading lower after the company announced it approved...
今天 04:41
FibroBiologics Approves 1-For-20 Reverse Stock Split
The reverse stock split is expected to become effective at 12:01 a.m. Eastern Time on March 30, 2026, with trading on a split-adjusted basis beginning on The Nasdaq Capital Market upon the commencement of trading on
今天 04:31
FibroBiologics Completes Onboarding Of Clinical Sites For Phase 1/2 Clinical Trial Evaluating Safety And Efficacy Of CYWC628 For Treatment Of Refractory DFUs
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases
03-05 21:32
FibroBiologics Issued New U.S. Patent Entitled Fibroblast Cell Therapy for Treatment of Osteoporosis
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for
03-02 21:37
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
D. Boral Capital Maintains Buy on FibroBiologics, Lowers Price Target to $7
D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and lowers the price target from $15 to $7.
02-26 05:34
FibroBiologics, Inc. - Common Stock Q4 EPS $(0.03) Beats $(0.09) Estimate
FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.09) by 67.39 percent. This is a 66.67 percent increase over losses of
02-25 06:22
FibroBiologics Receives Nasdaq Compliance Extension Through April 13
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for
02-23 21:38
FibroBiologics Issued Canadian IP Office Patent
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for
02-05 21:38
